<table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl3" position="float"><object-id pub-id-type="doi">10.7554/eLife.02869.019</object-id><label>Table 3.</label><caption><p>Patients showing high maximal mutation frequency slope (MMFS)</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.02869.019">http://dx.doi.org/10.7554/eLife.02869.019</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patient</th><th>MMFS<xref ref-type="table-fn" rid="tblfn3">*</xref></th><th>Fast growing mutations</th><th>MCF1 (%)</th><th>MCF2 (%)</th><th>dT (moths)</th><th>Treatment</th><th>Richter syndrome transformation</th></tr></thead><tbody><tr><td>#52</td><td>117.7</td><td><italic>TP53</italic> (P152+)</td><td>2.1</td><td>11.4</td><td>&lt;1</td><td>None</td><td>Yes</td></tr><tr><td>#68</td><td>9.1</td><td><italic>TP53</italic> (R273C)</td><td>0.0</td><td>100.0</td><td>11</td><td>None</td><td>No</td></tr><tr><td>#51</td><td>6.7</td><td><italic>SF3B1</italic> (I704F)</td><td>12.2</td><td>68.9</td><td>5</td><td>RCVP</td><td>Yes</td></tr><tr><td>#37</td><td>6.4</td><td><italic>TP53</italic> (R248Q)</td><td>3.8</td><td>90.0</td><td>10</td><td>RDHAOX</td><td>Yes</td></tr><tr><td>#57</td><td>5.9</td><td><italic>NOTCH1</italic> (P2514-)</td><td>0.8</td><td>94.2</td><td>12</td><td>None</td><td>Yes</td></tr><tr><td>#47</td><td>4.6</td><td>del13q</td><td>37.6</td><td>100.0</td><td>13</td><td>None</td><td>No</td></tr><tr><td>#14</td><td>3.9</td><td>del17p</td><td>18.9</td><td>90.0</td><td>16</td><td>A</td><td>No</td></tr><tr><td>#42</td><td>3.4</td><td><italic>TP53</italic> (N239T)</td><td>0.0</td><td>100.0</td><td>16</td><td>RDHAOX</td><td>Yes</td></tr><tr><td>#4</td><td>3.3</td><td>del17p</td><td>53.6</td><td>100.0</td><td>15</td><td>CLB-O</td><td>No</td></tr><tr><td>#54</td><td>3.0</td><td><italic>NOTCH1</italic> (P2415-)</td><td>100.0<xref ref-type="table-fn" rid="tblfn4">&#8224;</xref></td><td>100.0</td><td>22</td><td>FCO</td><td>No</td></tr><tr><td>#22</td><td>2.9</td><td><italic>BIRC3</italic> deletion</td><td>0.0</td><td>93.9</td><td>29</td><td>FCR</td><td>No</td></tr><tr><td>#20</td><td>2.8</td><td>del13q</td><td>0.0</td><td>100.0</td><td>36</td><td>CLB</td><td>No</td></tr><tr><td>#63</td><td>2.5</td><td><italic>BIRC3</italic> (M388V)</td><td>0.0</td><td>86.0</td><td>24</td><td>FCR</td><td>Yes</td></tr><tr><td>#6</td><td>2.3</td><td>del17p</td><td>0.0</td><td>92.1</td><td>34</td><td>CLB</td><td>No</td></tr><tr><td>#38</td><td>2.3</td><td><italic>NOTCH1</italic> (P2514-)</td><td>41.7</td><td>42.9</td><td>4</td><td>CVP</td><td>Yes</td></tr><tr><td>#13</td><td>2.2</td><td><italic>TP53</italic> (G136H)</td><td>0.0</td><td>100.0</td><td>45</td><td>RDHAOX</td><td>No</td></tr><tr><td>#1</td><td>2.1</td><td>del11q</td><td>11.8</td><td>100.0</td><td>41</td><td>FCR/A/BR</td><td>No</td></tr></tbody></table><table-wrap-foot><fn id="tblfn3"><label>*</label><p>MMFS, maximal mutation frequency slope (in standard deviation per year); MCF1, mutation cell frequency of selected mutation at the first time point; MCF2, mutation cell frequency at the second time point; dT, the elapsed time between two samples; RCVP, rituximab, cyclophosphamide, vincristine, prednisone; RDHAOX, rituximab, dexamethasone, high dose cytarabine, oxaliplatin; A, alemtuzumab; CLB-O, chlorambucil, ofatumumab; FCO, fludarabine, cyclophosphamide, ofatumumab; FCR, fludarabine, cyclophosphamide, rituximab; CLB, chlorambucil; CVP, rituximab, cyclophosphamide, vincristine, prednisone; BR, bendamustine, rituximab.</p></fn><fn id="tblfn4"><label>&#8224;</label><p>Total number of the cancer cells with <italic>NOTCH1</italic> alteration does not change, but the allele frequency of the mutation increases because of the deletion of the wild-type allele.</p></fn></table-wrap-foot></table-wrap>